ArticleBMC microbiology2014
Lactobacillus crispatus L1: high cell density cultivation and exopolysaccharide structure characterization to highlight potentially beneficial effects against vaginal pathogens.
Article in BMC microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 71 citations in OpenAlex.
- Methods for Detection, Extraction, Purification, and Characterization of Exopolysaccharides of Lactic Acid Bacteria-A Systematic Review.Foods (Basel, Switzerland) · 2024Review
- Vaginal dysbiosis and the potential of vaginal microbiome-directed therapeutics.Frontiers in microbiomes · 2024Review
- Protective Properties of S-layer Protein 2 fromBiomolecules · 2023Article
- The mobilome ofMicrobial genomics · 2023Article
- In Vitro Assessment of Lactobacillus crispatus UBLCp01, Lactobacillus gasseri UBLG36, and Lactobacillus johnsonii UBLJ01 as a Potential Vaginal Probiotic Candidate.Probiotics and antimicrobial proteins · 2023Article
- Exopolysaccharides from vaginal lactobacilli modulate microbial biofilms.Microbial cell factories · 2023Article
- The analysis ofFrontiers in microbiology · 2023Article
- Article
- Lactic Acid Bacteria Exopolysaccharides Producers: A Sustainable Tool for Functional Foods.Foods (Basel, Switzerland) · 2021Review
- The Complex Link between the Female Genital Microbiota, Genital Infections, and Inflammation.Infection and immunity · 2021Review
- Probiotic Effector Compounds: Current Knowledge and Future Perspectives.Frontiers in microbiology · 2021Review
- Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health.Microbial cell factories · 2020Review
- Cervicovaginal Microbiome Composition Is Associated with Metabolic Profiles in Healthy Pregnancy.mBio · 2020Article
- Genetic and Phenotypic Characteristics of a Multi-strain Probiotic for Broilers.Current microbiology · 2020Article
- Host and body site-specific adaptation ofNAR genomics and bioinformatics · 2020Article
- The role of Lactobacillus species in the control of Candida via biotrophic interactions.Microbial cell (Graz, Austria) · 2019Review
- KeepingDisease models & mechanisms · 2019Article
- Genome editing using the endogenous type I CRISPR-Cas system inProceedings of the National Academy of Sciences of the United States of America · 2019Article
- The relationship between the structural characteristics of lactobacilli-EPS and its ability to induce apoptosis in colon cancer cells in vitro.Scientific reports · 2019Article
- Fungal-Bacterial Interactions in Health and Disease.Pathogens (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVaginal lactic acid bacteria defend the host against pathogens through a combination of competitive exclusion, competition for nutrients, production of antimicrobial substances and through the activation of the immune system. A new human isolate named Lactobacillus crispatus L1 was characterized in this work, and a preliminary evaluation of its probiotic potential is described together with a process to obtain a high productivity of viable biomass.
resultsIn a simulated digestion process 1.8⋅10(10) cells∙ml(-1) survived the gastric environment with 80% viability, without being affected by small intestine juices. Experiments on six different C sources were performed to analyze growth and organic acids production and, glucose, provided the best performances. A microfiltration strategy was exploited to improve the cellular yield in 2 L-fermentation processes, reaching 27 g · l(-1) of dry biomass. Moreover, L. crispatus L1 demonstrated a greater stability to high concentrations of lactic acid, compared to other lactobacilli. The specific L. crispatus L1 exopolysaccharide was purified from the fermentation broth and characterized by NMR showing structural features and similarity to exopolysaccharides produced by pathogenic strains. Live L. crispatus L1 cells strongly reduced adhesion of a yeast pathogenic strain, Candida albicans in particular, in adherence assays. Interestingly a higher expression of the human defensin HBD-2 was also observed in vaginal cells treated with the purified exopolysaccharide, indicating a possible correlation with C. albicans growth inhibition.
conclusionsThe paper describes the evaluation of L. crispatus L1 as potential vaginal probiotic and the fermentation processes to obtain high concentrations of viable cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.